# Alzheimer Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/alzheimer-disease

> 11 upcoming FDA catalysts in Alzheimer Disease: karxt (BMY) on November 2026 (primary completion); JNJ-64042056 (JNJ) on Dec 2026 to Mar 2027 (topline data readout); JNJ-64042056 (JNJ) on December 2026 (primary completion); donanemab (LLY) on November 2027 (primary completion); and 7 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 30, 2025 | [Primec primary completion](https://sec-api.dev/pdufa/primec) | NRSN | Alzheimer Disease | withdrawn | "NCT06185543 (A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor NeuroSense Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06185543)) |
| May 1, 2026 | [Mevidalen primary completion](https://sec-api.dev/pdufa/mevidalen) | LLY | Alzheimer Disease | completed | "NCT06538116 (A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06538116)) |
| October 29, 2026 | [Sabirnetug primary completion](https://sec-api.dev/pdufa/sabirnetug) | ABOS | Alzheimer Disease | completed | "NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Acumen Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06335173)) |
| Nov 2026 to Feb 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| Dec 2026 to Mar 2027 | [JNJ-64042056 topline data readout](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| December 2026 | [JNJ-64042056 primary completion](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| November 2027 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT05026866 (A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05026866)) |
| Nov 2027 to Feb 2028 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT05026866 (A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05026866)) |
| March 2028 | [[18f]pi-2620 primary completion](https://sec-api.dev/pdufa/18f-pi-2620) | LNTH | Alzheimer Disease | scheduled | "NCT05641688 ([18F]PI-2620 Phase 3 Histopathological Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Lantheus Biosciences Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05641688)) |
| Mar to Jun 2028 | [[18f]pi-2620 topline data readout](https://sec-api.dev/pdufa/18f-pi-2620) | LNTH | Alzheimer Disease | scheduled | "NCT05641688 ([18F]PI-2620 Phase 3 Histopathological Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Lantheus Biosciences Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05641688)) |
| Nov 2028 to Feb 2029 | [Xanomeline/trospium chloride topline data readout](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer Disease | scheduled | "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011732)) |
| November 2028 | [Xanomeline/trospium chloride primary completion](https://sec-api.dev/pdufa/xanomeline-trospium) | BMY | Alzheimer Disease | scheduled | "NCT07011732 (A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011732)) |
| April 2030 | [Donanemab primary completion](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT07571161 (Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571161)) |
| Apr to Jul 2030 | [Donanemab topline data readout](https://sec-api.dev/pdufa/donanemab) | LLY | Alzheimer Disease | scheduled | "NCT07571161 (Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07571161)) |

## Drugs

- [Primec](https://sec-api.dev/pdufa/primec) (NRSN)
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen) (LLY)
- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug) (ABOS)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056) (JNJ)
- [Donanemab](https://sec-api.dev/pdufa/donanemab) (LLY)
- [[18f]pi-2620](https://sec-api.dev/pdufa/18f-pi-2620) (LNTH)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/alzheimer-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Alzheimer Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/alzheimer-disease

```bibtex
@misc{secapidev_indications_alzheimer_disease_20261116,
  title        = {Alzheimer Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/alzheimer-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_alzheimer_disease_20261116","title":"Alzheimer Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/alzheimer-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
